Related Experiment Videos
Sarcomatoid differentiation in renal cell carcinoma: prognostic implications
Marcos F Dall'Oglio1, Marco Lieberknecht, Valter Gouveia
1Division of Urology, Paulista School of Medicine, Federal University of Sao Paulo, UNIFESP, Sao Paulo, SP, Brazil. marcosdallogliouro@terra.com.br
Summary
Renal cell carcinoma with sarcomatoid differentiation is aggressive and resistant to immunotherapy. Surgical resection combined with immunotherapy may offer a therapeutic response in select cases.
Area of Science:
- Oncology
- Urologic Oncology
- Nephrology
Background:
- Sarcomatoid differentiation in renal cell carcinoma (RCC) indicates aggressive tumor behavior.
- This subtype of RCC is known for its poor response to conventional immunotherapy treatments.
Purpose of the Study:
- To report the clinical experience and treatment outcomes of 15 patients with renal cell carcinoma with sarcomatoid differentiation.
- To assess the survival rates and response to adjuvant immunotherapy in this patient cohort.
Main Methods:
- Retrospective analysis of 15 consecutive cases of sarcomatoid RCC diagnosed between 1991 and 2003.
- Evaluation of clinical presentation, pathological stage, tumor features, immunotherapy use, and survival data.
- Primary endpoint focused on assessing overall survival for individuals with this rare RCC subtype.
Main Results:
- The study included 15 patients (8 female, 7 male; mean age 63 years).
- 87% of patients were symptomatic at presentation, with 4 individuals having metastatic disease.
- High-grade tumors with necrosis (87%) and microvascular invasion (80%) were common; disease-free and cancer-specific survival rates were 40% and 46%, respectively. Two patients responded to adjuvant immunotherapy.
Conclusions:
- Patients diagnosed with sarcomatoid renal tumors face a generally poor prognosis and low life expectancy.
- Combination therapy involving surgical resection and immunotherapy may achieve a durable therapeutic response in some patients.